NeuroStorm

NeuroStorm is developing Digital Medicines, particularly Software as a Medical Device (SaMD) technologies for parkinsonian tremor. We have developed and tested algorithms to eliminate tremors in Virtual Reality (VR). These algorithms enable Parkinson's patients (and members of other movement disorder populations) to function normally in VR. Additionally and importantly, this smart use of VR results in Parkinson's patients having less tremors in real life. We are working with healthcare providers to bring our technology to market as metaverse Software as a Medical Device (SaMD), an emerging segment of medicine (just approved by the FDA in 2021) so one day our technology will be prescribed by physicians just as would be done for a therapeutic pill or surgical instrument. See our latest publication: Algorithmic Virtual Reality Reduces Parkinsonian Tremor. Cornacchioli et al., medRxiv 2023. https://www.medrxiv.org/content/10.1101/2023.02.05.22283323v1 See our clinical trial (NCT05666674, 2023, Enrolling by invitation): https://clinicaltrials.gov/ct2/show/NCT05666674

所属行业

医院和医疗保健

规模

2-10 人

总部

New York，NY

类型

非营利机构

创立

2019

领域

virtual reality、neuroscience、neurology、augmented reality、VR、AR、mixed reality、MR、biology、perception、science、technology、data、medicine、entertainment、marketing、Parkinson's disease、Software as Medical Device、SaMD和Digital Medicine